Provid Pharmaceuticals Inc. is actively seeking investment or a research collaboration partner for the development of PV-3212, the company’s novel, small molecule drug candidate for the treatment of multiple sclerosis (MS) and other autoimmune diseases. PV-3212 is a picomolar inhibitor of the major histocompatibility (MHC) class II molecule HLA DRB1*15:01 (“DR15”), the immune target genetically associated with MS and Goodpasture’s disease and implicated in prodromal Parkinson’s disease. Specific inhibition of DR15 promises high efficacy in treating disease in DR15 patients without compromising normal immune responses. PV-3212 has potent activity, high metabolic stability, and 20+ years of patent life.